Spontaneous primary hypothyroidism in adults is usually associated with autoimmune thyroiditis. The hypothesis that hypothyroidism may result from the presence in serum of a factor that blocks stimulation of the thyroid by thyroid stimulating hormone was examined. Serum samples were collected from 28 patients with recently diagnosed primary hypothyroidism. After removal of endogenous thyroid stimulating hormone the effect of the serum on secretion of triiodothyronine induced by thyroid stimulating hormone or thyroid stimulating antibodies was examined in thyroid slices incubated in vitro. Serum samples from six of the patients demonstrated significant blocking of the stimulation by bovine thyroid stimulating hormone. Inhibition of the stimulatory action of thyroid stimulating antibodies was also exhibited by serum samples with blocking activity.
Introduction
Most cases of spontaneous primary hypothyroidism in adults are considered to be due to chronic autoimmune thyroiditis, in which there is a progressive destruction of the thyroid gland such that, ultimately, insufficient functional thyroid tissue remains to maintain normal serum concentrations of the thyroid hormones triiodothyronine and thyroxine despite maximal pituitary drive by thyroid stimulating hormone. The inability of the thyroid gland in primary myxoedema to respond to the stimulatory action of the excess thyroid stimulating hormone has generally been attributed to the extent of the glandular destruction. However, the presence in serum from such patients of antibodies that block stimulation of the thyroid by thyroid stimulating hormone is another possible pathogenic mechanism. In 1980 Matsuura et al reported transient neonatal hypothyroidism in two siblings whose serum IgG inhibited the stimulation of thyroidal adenylate cyclase by thyroid stimulating hormone. ' Endo et al reported that serum from an adult with autoimmune hypothyroidism contained IgG with similar inhibitory properties.2 We studied serum samples from adults with primary hypothyroidism for the ability to block the effect of thyroid stimulating hormone, using a biological assay that measures the secretion of triiodothyronine from slices of thyroid incubated in vitro.3 Patients and methods Serum samples were collected from 28 patients with biochemically confirmed primary hypothyroidism (low serum thyroxine and high thyroid stimulating hormone concentrations) at, or near, the time of diagnosis. The group comprised four men and 24 women with a mean age of 52-3 years (table I). All but three patients had a high titre of microsomal antibodies; 10 patients had appreciable titres of antithyroglobulin antibodies; and goitre was present in 13 patients. Serum was also collected from 15 normal subjects, who served as controls. Serum was stored at -40°C until assay.
REMOVAL OF ENDOGENOUS THYROID STIMULATING HORMONE
Endogenous thyroid stimulating hormone, which is present in high concentrations in the serum of patients with primary hypothyroidism, produces detectable stimulation in the thyroid slice bioassay (limit of detection about 25 mU/l) and thus would interfere with the detection of the hormone blocking activity. The hormone was therefore removed from all serum samples by a solid phase affinity technique before examination in the bioassay. Antiserum to human thyroid stimulating hormone (raised in the guinea pig) was coupled to Having been heated at 56°C for 30 minutes after removal of endogenous thyroid stimulating hormone, the serum samples were assayed for biological activity by measuring their effect on the response to bovine thyroid stimulating hormone (0-2 U/1) of secretion of free triiodothyronine from slices of porcine thyroid incubated in vitro, as previously described.3 Two slices (1 x 1 x 0 5 mm) of porcine thyroid tissue were placed with 100 ,1l of serum on a Visking dialysis membrane in a diffusion pot with two compartments containing 5 ml buffer (HEPES/gelatin/Earles balanced salts; pH 7 4). The pots were incubated at 37°C for five hours. The tissue was then washed with 200 ,l buffer and removed. The pots were sealed and incubated for a further 18 hours at 37°C in a shaking waterbath to allow free thyroid hormones, released by the thyroid tissue in response to stimulation, to dialyse across the membranes. Free triiodothyronine in the dialysate was measured by radioimmunoassay.
Pooled normal serum obtained from 15 healthy members of the laboratory staff was similarly prepared and included in each assay as a control. Assays included five replicates for each serum sample and were repeated on at least two occasions. Blocking activity was considered to be demonstrated if the amount of free triiodothyronine released by bovine thyroid stimulating hormone in the test serum was significantly lower than that released when the bovine thyroid stimulating hormone was incubated in pooled normal serum. To establish the nature of the blocking activity antiserum to human IgG (Fc) (nephelometric grade from Seward Laboratory) was included in some later experiments. Aliquots of serum free of thyroid stimulating hormone (750 ,ul) were incubated with 500 ,l anti-IgG for one hour before addition of bovine thyroid stimulating hormone (to give a final concentration of 0-2 U/I). The serum samples were then assayed as before for the presence of blocking activity; serum samples preincubated with buffer in the same proportions were included as controls.
ASSAY FOR THYROTROPHIN BINDING INHIBITORY IMMUNOGLOBULINS
Immunoglobulin concentrates were prepared from serum samples by precipitation with macrogol (polyethylene glycol) 4000, as described by Shewring and Rees Smith.5 The immunoglobulin preparations were assayed for their ability to inhibit binding of bovine thyroid stimulating hormone labelled with iodine-125 (125I) to thyroid stimulating hormone receptors solubilised from porcine thyroid tissue with Triton X-100, and to particulate porcine thyroid membranes prepared by differential centrifugation of tissue homogenate in hypotonic medium.6 Solubilised porcine thyroid plasma membranes (50 ,ul (80 ,ug protein) ) in 10 mM trometamol (TRIS) and hydrochloric acid (pH 7 4) were incubated with 50 Ml immunoglobulin concentrate (10 g/l) and 50 Ml 125I bovine thyroid stimulating hormone (4000 counts/min) for 30 minutes at 37°C in a shaking waterbath. The reaction was stopped by adding 500 ml bovine IgG (2 g/l in 10 mM trometamol and hydrochloric acid (pH 7-4)) and 650 ,ul of 30% (w/v) macrogel 4000 in 1 M sodium chloride to each tube. After mixing the samples were centrifuged at 4000 g for 20 minutes at 4°C, the supernatant aspirated, and radioactivity in the pellet counted. Contversionz: SI to traditional zonits-Triiodothyronine: 1 pimolll 0 65 pg/ml. figure) . Similarly, thyrotrophin binding inhibitory immunoglobulin was not detected when particulate thyroid membranes were used.
There were no clinical features that distinguished the patients whose serum contained blocking activity from those whose serum did not (table I). All six patients with blocking activity in their serum (two men, four women) had a high titre of thyroid microsomal antibodies, and three had detectable antithyroglobulin antibodies; two had a goitre at presentation. Of the 22 without blocking activity, 19 had demonstrable microsomal antibodies and seven had antithyroglobulin antibodies; 11 had a goitre.
Discussion
This study showed that serum from some patients with primary hypothyroidism contains a factor that inhibits stimulation of the thyroid by thyroid stimulating hormone and thyroid stimulating antibodies. The degree of inhibition of thyroid hormone secretion at the concentration of thyroid stimulating hormone used in this study suggests that this in vitro phenomenon is relevant clinically and that the blocking activity probably has an important role in the pathogenesis of primary hypothyroidism.
The blocking effect observed could be explained by interference at the level of the thyroid stimulating hormone receptor or a postreceptor mechanism, or by binding of the hormone to a factor present in the serum, preventing it from interacting with the hormone receptor. Specific binding of thyroid stimulating hormone by human serum globulins has been described,7 8 but this possibility was excluded in this study. Furthermore, this mechanism of blocking would not explain the inhibition of the stimulatory effect of thyroid stimulating antibodies that we found. From these results we might postulate that there is inhibition of binding of thyroid stimulating hormone to its receptor due to the presence of serum factors blocking the interaction between the hormone and the receptor. None of the patients reported on here, however, had demonstrable thyrotrophin binding inhibitory immunoglobulin activity. This discrepancy between the receptor binding data and the effect on release of triiodothyronine stimulated by thyroid stimulating hormone might suggest either that the interference occurs at a membrane site remote from, but influencing, the hormone receptor or that postreceptor mechanisms play a part. Further work is planned to clarify the site of blockade of the action of thyroid stimulating hormone. The nature of the factor that blocks the hormone's action has not been fully defined, but preliminary studies using anti-IgG indicate that it is almost certainly an IgG. Studies to confirm this are in progress.
No correlation has been found between the presence or absence of goitre and the occurrence of blocking activity in the serum. This implies that the blocking activity shown in the thyroid slice bioassay is distinct from the antibodies blocking thyroid growth that have been reported to be present in the serum of patients with primary hypothyroidism.9 Likewise, there is no correlation between the presence of blocking activity and a high titre of thyroid autoantibodies as measured by haemagglutination.
There have been previous reports of antibodies that block the action of thyroid stimulating hormone in primary hypothyroidism. Using immunoglobulin G preparations, inhibition of stimulation by thyroid stimulating hormone of adenylate cyclase activity in human thyroid membrane preparations was demonstrated in serum from a patient with hypothyroidism secondary to Hashimoto's 
Patients and methods
Five girls aged from 11 months to 4 years 9 months were diagnosed as having infantile hypothyroidism on the basis of clinical findings together with low serum thyroxine concentrations and raised thyroid stimulating hormone concentrations in the blood. Serum immunoglobulin concentrations were measured by single radial immunodiffusion (Partigen plates, Hoechst). Blood was taken from each child at the time of diagnosis and again whenever thyroid function tests were monitored during treatment with thyroxine sodium.
Results
In all five girls serum IgA concentrations fell after treatment with thyroxine was started (figure) . In four of them IgA concentrations fell below the range of normal for healthy British children.2 In one child the serum IgA concentration fell to less than 0-01 g/l and remained reduced. IgA concentrations returned to normal in the other four and then increased with age in the usual way. Concentrations of IgG and IgM generally fluctuated within the normal range during treatment; one child, however, had a marginally low IgG concentration at seven months, and three children developed marginally raised IgM concentrations between 18 months and three years after the start of treatment.
The child who developed long lasting IgA deficiency subsequently did not show any evidence of recurrent infection or allergic disease. Four years after the start of treatment with thyroxine her serum gave a negative result when tested for thyroid microsomal and colloid antibodies.
Discussion
Physical and intellectual development are delayed in children with infantile hypothyroidism. The development of their
